Unknown

Dataset Information

0

Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial.


ABSTRACT: Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

SUBMITTER: Fogel JM 

PROVIDER: S-EPMC4911290 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial.

Fogel Jessica M JM   Hudelson Sarah E SE   Ou San-San SS   Hart Stephen S   Wallis Carole C   Morgado Mariza G MG   Saravanan Shanmugam S   Tripathy Srikanth S   Hovind Laura L   Piwowar-Manning Estelle E   Sabin Devin D   McCauley Marybeth M   Gamble Theresa T   Zhang Xinyi C XC   Eron Joseph J JJ   Gallant Joel E JE   Kumwenda Johnstone J   Makhema Joseph J   Kumarasamy Nagalingeswaran N   Chariyalertsak Suwat S   Hakim James J   Badal-Faesen Sharlaa S   Akelo Victor V   Hosseinipour Mina C MC   Santos Breno R BR   Godbole Sheela V SV   Pilotto Jose H JH   Grinsztejn Beatriz B   Panchia Ravindre R   Mayer Kenneth H KH   Chen Ying Q YQ   Cohen Myron S MS   Eshleman Susan H SH  

Journal of acquired immune deficiency syndromes (1999) 20160701 3


Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education  ...[more]

Similar Datasets

| S-EPMC3805242 | biostudies-other
| S-EPMC3486723 | biostudies-other
| S-EPMC5140698 | biostudies-literature
| S-EPMC3209811 | biostudies-literature
| S-EPMC7823077 | biostudies-literature
| S-EPMC3782474 | biostudies-literature
| S-EPMC4596522 | biostudies-other
| S-EPMC4911239 | biostudies-literature
| S-EPMC4482803 | biostudies-literature
| S-EPMC5393630 | biostudies-literature